PKI

珀金埃尔默
NYSE

实时行情|Nasdaq Last Sale

93.41
+0.91
+0.98%
盘后: 93.41 0 0.00% 16:00 05/22 EDT
开盘
92.95
昨收
92.50
最高
93.65
最低
92.34
成交量
47.46万
成交额
--
52周最高
102.46
52周最低
62.91
市值
103.97亿
市盈率(TTM)
45.79
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PKI价格均价为98.83,最高价位110.00,最低价为85.00。

EPS

PKI 新闻

更多
PerkinElmer to Present at Jefferies Global Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the (virtual) Jefferies Global Healthcare Conference on Thursday, June 4, 2020 at 9:00 a.m. ET.
Business Wire · 5天前
PerkinElmer faces probe over alleged Medicare fraud - Reuters
Seeking Alpha - Article · 05/18 14:00
PerkinElmer denies Reuters report that it is being investigated in a Medicare fraud case
PerkinElmer Inc. said Monday that it has not received any information, and is not aware of any wrongdoing, as implied by a Reuters report. The diagnostics and health services company also said it did not have any information that it or any of its personnel ar
MarketWatch · 05/18 13:44
Official Statement from PerkinElmer in Response to Reuters Article Published on May 18, 2020
PerkinElmer, Inc. (NYSE: PKI) supports government efforts to identify and prevent abusive practices in healthcare. PerkinElmer has received subpoenas from the government regarding investigations into third parties, and has fully cooperated with authorities and
Business Wire · 05/18 13:28
Exclusive: U.S. probes PerkinElmer's role in massive Medicare fraud - sources
Medical diagnostic firm PerkinElmer Inc <PKI.N> faces a federal investigation into its role in an alleged Medicare fraud involving tens of thousands of unnecessary genetic cancer tests, according to three sources with knowledge of the probe and documents revie
Reuters · 05/18 11:17
PerkinElmer, Inc. -- Moody's announces completion of a periodic review of ratings of PerkinElmer, Inc.
Moody's · 05/15 20:04
PerkinElmer: The Market Completely Missed The Transformation
Seeking Alpha - Article · 05/07 20:32
UBS Maintains Neutral on PerkinElmer, Raises Price Target to $96
UBS maintains PerkinElmer (NYSE:PKI) with a Neutral and raises the price target from $95 to $96.
Benzinga · 05/07 16:19

所属板块

先进医疗设备和技术
+1.36%
医疗设备和用品
+1.09%

热门股票

代码
价格
涨跌幅

PKI 简况

PerkinElmer Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. Its Discovery & Analytical Solutions segment serves the life sciences and applied markets. Through the Diagnostics Segment, it offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals. It provides early detection for genetic disorders from pregnancy to early childhood, and infectious disease testing for the diagnostics market. It offers its product under various brands, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BoBs, chemagic, FragilEase, Genoglyphix, GSP, PG-Seq, PG-Find, Protein Clear, ProteinEXact and QSight, Glutomatic, Honigs Regression, HyperDSC, Inframatic, LAMBDA, NexION, NEN, OneSource, Opera Phenix, Operetta CLS and OsteoSense.
展开

微牛提供PerkinElmer, Inc.(NYSE-PKI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PKI股票新闻,以帮助您做出投资决策。